Hylartin® V Injection Hylartin® V — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Hylartin® V Injection Hylartin® V

Active ingredient

Hyaluronate Sodium

Application type

NADA

Sponsor

Zoetis Inc.

Applications on record

1

First published

June 1, 2016

Adverse event reports

Source: openFDA VeDDRA

1,068

Reports mentioning this ingredient

February 4, 1987 – March 13, 2026

143

Classified serious

per reporter assessment

12

Lack of expected efficacy

resistance signal

0

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “HYALURONATE SODIUM”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Lameness	139
Joint swelling	120
Product syringe issue	105
Stopper, abnormal	101
Syringe, Abnormal	95
Joint effusion	67
Uncoded sign	63
Joint pain	51
Joint inflammation	46
Illness NOS	46
Vials, Damaged	39
Underfilling, Vials	37
Injection site swelling	31
No sign	31
Fever	27
Seal, Abnormal	25
Septic arthritis	24
Synovitis	24
Death by euthanasia	23
Injection site inflammation	22

Species affected

Source: openFDA VeDDRA

Horse 497 Dog 26 Human 2 Other 1 Cat 1 Rabbit 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient